Abstract
Systemic chemotherapy may be the appropriate treatment of liver metastases if the primary cancer is sensitive to chemotherapy. Metastases, however, are known to be sometimes less sensitive to chemotherapy than the primary tumor [1]. Depending on the nature of the neoplastic liver lesions, different rates of response to the treatment have been obtained.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Maehara Y, Sakaguchi Y, Emi Y, Kusumoto T, Kohnoe S, Mori M, Sugimachi K (1990) Primary and metastatic liver lesions of clinical colorectal cancer differ in chemosensitivity. Int J Colorectal Dis 5: 87–89
Wanebo HJ, Falkson G, Order S (1989) Cancer of the hepatobiliary tract. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology, 3rd edn. Lippincott, Philadelphia
Falkson G, Coetzer BJ, Terblanche APS (1984) Phase II trial of mitoxantrone in patients with primary liver cancer. Cancer Treat Rep Suppl 10, 68: 1311–1312
Baker LH, Saiki JH, Jones SE et al. (1977) Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma. A Southwest Oncology Group study. Cancer Treat Rep 61: 1595–1597
Al-Hidrissi, Ibrahim E, Satir A et al. (1985) Primary hepatocellular cancer in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C. Hepatogastroenterology 32: 8–10
Ravery MJR, Omura GA, Bartolucci AA (1984) Phase II evaluation of epidoxorubicin plus bleomycin in hepatocellular carcinoma. A Southeastern Cancer Group trial. Cancer Treat Rep 68: 1517–1518
Melia WM, Johnson PJ, Williams R (1987) Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 71: 1213–1216
Farinati F, Salvagnini M, de Maria N, Fornasiero A, Chiaramonte M, Rossaro L, Naccarato R (1990) Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 11: 297–301
Poplin EA, Kraut M, Baker L, Brodfuehrer J, Vaitkevicius V (1991) A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma. Cancer 67: 367–371
Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM et al. (1990) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 7: 1419–1426 [Published erratum appears in J Clin Oncol (1990) 8: 185]
Kemeny N, Sugarbaker PH (1989) Treatment of metastatic cancer to liver. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology, 3rd Edn. Lippincott, Philadelphia
Fernandez Hidalgo O, Gonzalez F, Gil A, Campbell W, Barrajon E, Lacave AJ (1989) 120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am J Clin Oncol 12: 397–401
Colozza M, Gori S, Mosconi AM, Belsanti V, Basurto C, Rossetti R, Di Costanzo F, Buzzi F, Bacchi M, Davis S et al. (1989) Chemotherapy with cis-platin, doxorubicin, and cyclophosphamide (CAP) in patients with metastatic breast cancer. Am J Clin Oncol 12: 137–141
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hoogewoud, HM. (1993). Systemic Chemotherapy. In: Hepatocellular Carcinoma and Liver Metastases: Diagnosis and Treatment. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77981-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-77981-7_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77983-1
Online ISBN: 978-3-642-77981-7
eBook Packages: Springer Book Archive